Nuvation Bio (NUVB) Stock Trades Below Fair Value After Its 211% Run
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients
What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call
RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17
Nuvation Bio (NUVB) Q3 2026 Earnings Call Transcript
Nuvation Bio (NYSE:NUVB) Posts Revenue Beat as IBTROZI Momentum Faces After-Hours Pullback
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio Q3 2026 Earnings Call Transcript
Nuvation Bio Q3 EPS $(0.12), Inline, Sales $44.951M Beat $34.224M Estimate
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
Citigroup Initiates Coverage of Nuvation Bio with Buy
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.